71822-97-4

Basic information

• Product Name: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one
• Synonyms: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one;3-amino-6-bromo-2-methyl-4-quinazolinone;3-amino-6-bromo-2-methyl-quinazolin-4-one;3-amino-6-bromo-2-methylquinazolin-4-one
• CAS NO: 71822-97-4
• Molecular Formula: C₉H₈BrN₃O
• Molecular Weight: 254.08332
• Mol File: 71822-97-4.mol
• Article Data: 10

Chemical Properties

• Melting Point: 196 °C(Solv: ethanol (64-17-5))
• Boiling Point: 412.5±47.0 °C(Predicted)
• Appearance: /
• Density: 1.79±0.1 g/cm3(Predicted)
• Storage Temp.: 2-8°C
• PKA: -1.21±0.70(Predicted)
• CAS DataBase Reference: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one(71822-97-4)
• EPA Substance Registry System: 3-amino-6-bromo-2-methylquinazolin-4(3H)-one(71822-97-4)

Safety Data

• Hazardous Substances Data: 71822-97-4(Hazardous Substances Data)

Upstream product

• 118-92-3 anthranilic acid 
• 38985-79-4 5-bromo-N-acetylanthranilic acid 
• 5794-88-7 5-Bromo-2-aminobenzoic acid 
• 19165-25-4 2-methyl-6-bromo-4H-3,1-benzoxazine-4-one 

Downstream Products

• 1119264-27-5 C₁₇H₁₄BrN₃O₂ 
• 1119264-28-6 C₁₆H₁₂BrN₃O₂ 
• 71823-00-2 3-benzylideneamino-6-bromo-2-methyl-3H-quinazolin-4-one 
• 1119264-26-4 C₁₆H₁₁BrClN₃O 
• 117054-62-3 1-(6-Bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-5-[(2-chloro-phenylamino)-methyl]-3-phenyl-2-thioxo-dihydro-pyrimidine-4,6-dione 
• 117054-54-3 1-(6-Bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-3-phenyl-5-phenylaminomethyl-2-thioxo-dihydro-pyrimidine-4,6-dione 
• 117077-73-3 1-(6-Bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-5-[1-(3-chloro-phenyl)-meth-(Z)-ylidene]-3-phenyl-2-thioxo-dihydro-pyrimidine-4,6-dione 
• 117054-40-7 1-(6-Bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-3-phenyl-5-[1-phenyl-meth-(Z)-ylidene]-2-thioxo-dihydro-pyrimidine-4,6-dione 
• 117054-30-5 1-(6-Bromo-2-methyl-4-oxo-4H-quinazolin-3-yl)-3-phenyl-2-thioxo-dihydro-pyrimidine-4,6-dione 
• 150391-68-7 C₂₅H₁₈BrClN₆O 
• 518292-76-7 3-[(5-p-hydroxy-m-methoxybenzylideneamino-1,3,4-thiadiazol-2-yl)methylamino]-6-bromo-2-methylquinazolin-4(3H)-one 

Relevant articles and documents

Synthesis and evaluation of anticancer, antiphospholipases, antiproteases, and antimetabolic syndrome activities of some 3H-quinazolin-4-one derivatives

Some new 3H-quinazolin-4-one derivatives were synthesised and screened for anticancer, antiphospholipases, antiproteases, and antimetabolic syndrome activities. Compound 15d was more potent in reducing the cell viabilities of HT-29 and SW620 cells lines to 38%, 36.7%, compared to 5-FU which demonstrated cell viabilities of 65.9 and 42.7% respectively. The IC50 values of 15d were ～20?μg/ml. Assessment of apoptotic activity revealed that 15d decreased the cell viability by down regulating Bcl2 and BclxL. Moreover, compounds, 8j, 8d/15a/15e, 5b, and 8f displayed lowered IC50 values than oleanolic acid against proinflammatory isoforms of hGV, hG-X, NmPLA2, and AmPLA2. In addition, 8d, 8h, 8j, 15a, 15b, 15e, and 15f showed better anti-α-amylase than quercetin, whereas 8g, 8h, and 8i showed higher anti-α-glucosidase activity than allopurinol. Thus, these compounds can be considered as potential antidiabetic agents. Finally, none of the compounds showed higher antiproteases or xanthine oxidase activities than the used reference drugs.

Quinazolinone platinum metal complexes: In silico design, synthesis and evaluation of anticancer activity

Dihydrofolate reductase (DHFR) has been explored as a target for the development of agents for wide variety of human diseases, including cancer, autoimmune and infectious diseases. Several metal complexes are being used in management of cancer. The square planar Pt(II) complex, cis PtCl2(NH3)2 turned out to be even more effective at forcing filamentous growth. Cisplatin is an inorganic heavy metal complex that has activity similar to cell-cycle-phase-nonspecific alkylating agents such as cyclophosphamide and some other Ni and Cu metal complexes. It produces intrastrand DNA cross-link and form DNA adducts, thus inhibiting the synthesis of DNA, RNA and proteins preferentially. in silico Screening of platinum metal complexes was performed by Vlife MDS 4.3 software. In this procedure, selection of molecule, selection of PDB, optimization of PDB and docking of molecules was carried out. Synthesis of metal complexes was done by multi component reaction method. Platinum metal complexes of quinazolinone Schiff bases prioritized by in silico studies were characterized by IR, TLC, NMR, XRD, FESEM and some physico-chemical parameters. Prioritized molecules were further evaluated by in vitro anticancer cell line assay on ten cell lines with adriamycin as standard. The results showed that the platinum metal complexes of qunazolinone Schiff bases can be potential anticancer agents through DHFR inhibitory mechanism.

2-{2"-carbomyl-5"-[3′-amino-2′-methylmono/ dihalosubstituted quinazolin-4′(3'h)-onomethylene]- 1",3",4"-oxadiazol-2"-yl}-4,5-dihydroimidazolines as potential antihypertensive agents

Twelve new 2- {2"-carbomyl - 5" - [3′-amino-2′ - methylmono / dihalosubstituted quinazolin- 4′ (3'H) - onomethylene] - 1",3",4" - oxadiazol-2"-yl} -4, 5- dihydroimidazolines were prepared and evaluated for their cardiovascular activity. The most active compound of this series is 2-{2"- carbomyl-5"-[3′-amino-2′-methyl-6-bromoquinazolin-4′(3'H)-onomethylene]-",3",4"-oxadiazol-2"- yl}-4,5-dihydroimidazolines i.e. compound VIc.